Precision BioSciences (DTIL) Scheduled to Post Earnings on Thursday

Precision BioSciences (NASDAQ:DTIL – Get Rating) is scheduled to release its earnings data before the market opens on Thursday, March 9th. Analysts expect Precision BioSciences to post earnings of ($0.24) per share for the quarter.

Precision BioSciences Stock Down 8.5 %

Shares of DTIL opened at $1.07 on Tuesday. The company has a market cap of $118.73 million, a PE ratio of -0.70 and a beta of 1.45. The business has a fifty day moving average of $1.20 and a 200 day moving average of $1.33. Precision BioSciences has a 52-week low of $0.95 and a 52-week high of $4.27. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.26.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DTIL. HC Wainwright lowered their price target on Precision BioSciences from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, November 10th. BTIG Research lowered their price target on Precision BioSciences to $6.00 in a research report on Tuesday, November 15th.

Institutional Trading of Precision BioSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its stake in Precision BioSciences by 4.0% in the first quarter. BlackRock Inc. now owns 4,566,690 shares of the company’s stock worth $14,067,000 after purchasing an additional 175,176 shares during the period. Vanguard Group Inc. increased its stake in Precision BioSciences by 12.2% in the third quarter. Vanguard Group Inc. now owns 3,895,147 shares of the company’s stock worth $5,063,000 after purchasing an additional 425,055 shares during the period. Renaissance Technologies LLC increased its stake in Precision BioSciences by 139.6% in the third quarter. Renaissance Technologies LLC now owns 2,172,666 shares of the company’s stock worth $2,824,000 after purchasing an additional 1,265,877 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Precision BioSciences by 1.2% during the fourth quarter. JPMorgan Chase & Co. now owns 1,589,804 shares of the company’s stock valued at $1,891,000 after buying an additional 19,457 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Precision BioSciences by 269.9% during the second quarter. Millennium Management LLC now owns 1,534,226 shares of the company’s stock valued at $2,455,000 after buying an additional 1,119,435 shares during the period. Hedge funds and other institutional investors own 50.50% of the company’s stock.

About Precision BioSciences

(Get Rating)

Precision BioSciences, Inc is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases.